BLVD201

BLVD201 (formerly MTS-128) is a trispecific T-cell engager (TCE) designed to deliver a durable immune reset in severe B cell-driven autoimmune diseases. The biologic simultaneously targets CD19 and B-cell maturation antigen (BCMA) on B cells and plasma cells, while engaging CD3 on T cells to induce targeted cytotoxicity. By dual-targeting CD19 and BCMA, BLVD201 aims to deplete both antibody-producing plasma cells and the B cells that replenish them, potentially overcoming the limitations of single-target approaches. Developed by Boulevard Bio (a Deerfield Management-backed company) and licensed from METiS TechBio, the molecule features a compact design intended to enable deep tissue penetration and efficacy at low doses. It is currently in IND-enabling studies.